Melatonin and cardiovascular disease: from mechanisms of action to potential clinical use (literature review)

O. M. Drapkina,A. V. Kontsevaya,A. V. Budnevsky,E. S. Ovsyannikov,E. S. Drobysheva,V. I. Bolotskih,A. V. Makeeva,M. V. Lushchik
DOI: https://doi.org/10.15829/1728-8800-2021-2892
2022-01-09
CARDIOVASCULAR THERAPY AND PREVENTION
Abstract:Cardiovascular disease remains the most relevant public health problem. Most cardiovascular diseases are associated with an atherosclerosis, the development of which is associated with inflammation and endothelial dysfunction. Melatonin is a neurohormone that is synthesized mainly in the pineal gland and plays a central role in the regulation of sleep and some other body cyclic processes. For a long time, melatonin was perceived as a substance that is effective in the treatment of circadian cycle impairments. At the same time, a large number of studies have accumulated recently that demonstrate a wider range of its biological effects, including anti-inflammatory, antioxidant, antihypertensive and, possibly, hypolipidemic. The review includes current data from experimental and clinical studies demonstrating the cardioprotective effects of melatonin in atherosclerosis, myocardial ischemia, and heart failure.
What problem does this paper attempt to address?